Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

33.3%

3 terminated/withdrawn out of 9 trials

Success Rate

62.5%

-24.0% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

5 of 5 completed trials have results

Key Signals

1 recruiting5 with results

Enrollment Performance

Analytics

Phase 1

6(66.7%)

Phase 2

3(33.3%)

9Total

Phase 1(6)

Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04890613Phase 1Recruiting

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Role: lead

NCT06202521Phase 2Terminated

CX-4945 in Viral Community Acquired Pneumonia

Role: lead

NCT03904862Phase 1Terminated

Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery

Role: collaborator

NCT03897036Phase 1Completed

Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)

Role: lead

NCT05817708Phase 1Completed

A Study of Silmitasertib (CX-4945) in Healthy Subject

Role: lead

NCT04663737Phase 2Completed

Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19

Role: lead

NCT04668209Phase 2Terminated

Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19)

Role: collaborator

NCT02719977Phase 1Completed

A Phase I Study of CX5461

Role: collaborator

NCT02128282Phase 1Completed

Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma

Role: lead

All 9 trials loaded